Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LifeMD, Inc.LFMD · Entity 6521 | Chief Technology Officer | August 22, 2025 | August 26, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LifeMD, Inc.
Report date August 22, 2025 · Filed August 26, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 175,000 |
Reported balance
After 2025-08-22 transaction · row 1
1 source rowRow 1 · 2025-08-22 · Grant · Acquired 25,000 · Balance 175,000 F1: Represents grant of performance stock which vested on August 22, 2025 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of performance stock which vested on August 22, 2025
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 22, 2025 Filed Aug 26, 2025 22:24 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000920 · form4.xml · nonDerivative · entry 1 Wijnker Dennis · CIK 0001902668 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 F1 · price: Represents grant of performance stock which vested on August 22, 2025 Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:54 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000365 · form4.xml · nonDerivative · entry 1 Wijnker Dennis · CIK 0001902668 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 F1 · price: Represents grant of performance stock which vested on March 31, 2025. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 21:38 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000278 · form4.xml · nonDerivative · entry 1 Wijnker Dennis · CIK 0001902668 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 F1 · price: Represents grant of performance stock which vested on March 7, 2025. Read SEC document |
| August 18, 2024 Filed Aug 20, 2024 15:10 UTC | LifeMD, Inc. LFMD · Entity 6521 | Disposition to issuerStock Option (Right to Buy) · Derivative | 80,000 | Not disclosed Strike: $3.78 | Not disclosed |
DisclosureSEC source: 0000912282-24-000578 · form4.xml · derivative · entry 3 Wijnker Dennis · CIK 0001902668 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires not disclosed F2 · price: The options are being cancelled in exchange for 205,000 restricted shares, with 40,000 shares vesting on January 1, 2025; 40,000 shares vesting on January 1, 2026; and a remaining 125,000 performance shares to be reported on settlement. The options vest and become exercisable in equal monthly tranches, based on passage of time, over the 36 months following the grant date December 29, 2021. F2 · derivative.exercise_date: The options are being cancelled in exchange for 205,000 restricted shares, with 40,000 shares vesting on January 1, 2025; 40,000 shares vesting on January 1, 2026; and a remaining 125,000 performance shares to be reported on settlement. The options vest and become exercisable in equal monthly tranches, based on passage of time, over the 36 months following the grant date December 29, 2021. F2 · derivative.expiration_date: The options are being cancelled in exchange for 205,000 restricted shares, with 40,000 shares vesting on January 1, 2025; 40,000 shares vesting on January 1, 2026; and a remaining 125,000 performance shares to be reported on settlement. The options vest and become exercisable in equal monthly tranches, based on passage of time, over the 36 months following the grant date December 29, 2021. Read SEC document |
| August 18, 2024 Filed Aug 20, 2024 15:10 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Stock | 80,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000912282-24-000578 · form4.xml · nonDerivative · entry 2 Wijnker Dennis · CIK 0001902668 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F2 · price: The options are being cancelled in exchange for 205,000 restricted shares, with 40,000 shares vesting on January 1, 2025; 40,000 shares vesting on January 1, 2026; and a remaining 125,000 performance shares to be reported on settlement. The options vest and become exercisable in equal monthly tranches, based on passage of time, over the 36 months following the grant date December 29, 2021. Read SEC document |
| April 04, 2022 Filed Aug 20, 2024 15:10 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000912282-24-000578 · form4.xml · nonDerivative · entry 1 Wijnker Dennis · CIK 0001902668 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · price: The restricted shares vest in full on April 4, 2025. Read SEC document |
| December 29, 2021 Filed Jan 6, 2022 21:42 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001362118-22-000004 · primary_doc.xml · derivative · entry 1 Wijnker Dennis · CIK 0001902668 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2026-12-29 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on December 29, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.